Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MaiLi Precise
- Development stage
- Unknown
- Lead developer
- Sinclair
- Administration
- Buccal, Intradermal
01
Overview
MaiLi Precise is a hyaluronic acid (HA)-based injectable dermal filler developed and marketed by Sinclair Pharma. As the finest-gauge product in the MaiLi range, it is specifically designed for finishing treatments, such as smoothing fine wrinkles, treating medium skin depressions, and redefining the lips. The gel is composed of 15 mg/ml of cross-linked hyaluronic acid and 3 mg/ml of lidocaine, manufactured using the patented OxiFree™ technology to preserve long molecular HA chains. This process results in a supple, spring-like gel with high projection power and longevity. MaiLi Precise is a CE-marked medical device administered intradermally or into the labial mucosa.
- Brand names
- MaiLi Precise
Beyond the preview
Go deeper on MaiLi Precise.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MaiLi Precise.